Pyrimidine Compound as Jak Kinase Inhibitor
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 62/577,852, filed Oct 27, 2017. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,308,646 | Pyrimidine Compound as Jak Kinase Inhibitor In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence | ||
| US 10,562,894 | Pyrimidine Compound as Jak Kinase Inhibitor In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence | ||
| US 10,774,080 | Pyrimidine Compound as Jak Kinase Inhibitor In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence | ||
| US 10,988,470 | Pyrimidine Compound as Jak Kinase Inhibitor In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence | ||
| US 11,420,965 | Pyrimidine Compound as Jak Kinase Inhibitor In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence | ||
| US 11,814,377 | Pyrimidine Compound as Jak Kinase Inhibitor In force · High confidence | Theravance Biopharma R&D IP, LLC | In force | High confidence | ||
| US 12,172,994 | Pyrimidine Compound as Jak Kinase Inhibitor In force · Medium confidence | Theravance Biopharma R&D IP, LLC | In force | Medium confidence |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.